Marbocyl SA 200mg Powder and Solvent for Solution for Injection
Species: Cats, Dogs
Therapeutic indication: Pharmaceuticals: Antimicrobials: Injections
Active ingredient: Marbofloxacin
Product: Marbocyl™ SA 200mg Powder and Solvent for Solution for Injection
Product index: Marbocyl SA 200mg
Presentation
Powder and solvent for solution for injection.
Uses
In dogs: Marbocyl SA is indicated:
‑ in the treatment of infected wounds and subcutaneous abcesses due to Staphylococcus intermedius, Staphylococcus aureus, Escherichia coli, Pasteurella spp. and Pseudomonas spp.
‑ in the treatment of lower urinary tract infections due to Escherichia coli and Proteus spp.
In cats: Marbocyl SA is indicated :
‑ in the treatment of infected wounds and subcutaneous abcesses due to Pasteurella multocida, Staphylococcus intermedius, Staphylococcus aureus, Staphylococcus spp., Enterobacter spp. and Klebsiella spp.
Marbofloxacin is inactive against anaerobic bacteria.
Dosage and administration
Reconstitution: – Before use, reconstitute the lyophilised powder using the solvent (water for injections) provided for the 200mg vial. Using aseptic technique, withdraw 20ml from the vial of solvent and add rapidly to the lyophilised powder. When reconstituted in this way, the solution will contain 10mg marbofloxacin per ml.
In dogs: the recommended doses and durations of treatment are:
For the treatment of infected wounds and subcutaneous abcesses- a single subcutaneous or intravenous injection, at a dosage of 2mg/kg (1ml/5kg), followed the next day by administration of Marbocyl Tablets daily at a dosage of 2mg/kg for 6 days.
For the treatment of lower urinary tract infections – a single subcutaneous or intravenous injection, at a dosage of 2mg/kg (1ml/5kg), followed the next day by administration of Marbocyl Tablets daily at 2mg/kg for at least 10 days and up to 28 days.
In cats: the recommended dose and duration of treatment is:
For the treatment of infected wounds and subcutaneous abscesses 2 mg/kg/day (0.2ml/kg/day), by subcutaneous or intravenous injection followed by subcutaneous injections for a total of 3 to 5 days.
Contra-indications, warnings, etc
Marbofloxacin should not be used in dogs aged less than 12 months or less than 18 months for exceptionally large breeds of dogs, such as Great Danes or Mastiffs with a longer growth period.
Studies carried out with laboratory animals showed no embryotoxic, foetotoxic or teratogenic effects. However, no specific studies have been carried out on pregnant cats or dogs.
The dosage of theophylline must be reduced when used concurrently.
Overdosage may cause acute signs in the form of neurological disorders, hypersalivation or trembling which should be treated symptomatically.
After subcutaneous administration, no undesirable effect is observed up to 2 times the maximum recommended therapeutic dose in dogs or 3 times the maximum recommended dose for cats. After i.v. administration at 4mg/kg, rare mild and transitory side effects have been reported: -ptyalism (excess salivation) – nervous disorders: vocalization, excitation, trembling (myoclonia).
Withdrawal period
Not applicable
Operator warning
People with known hypersensitivity to fluoroquinolones should avoid using this product. Wash hands after use.
Use during pregnancy and lactation
Studies carried out with laboratory animals showed no embryotoxic, foetotoxic or teratogenic effects. However, no specific studies have been carried out on pregnant cats or dogs.
Pharmaceutical precautions
Protect both lyophilized powder and reconstituted solutions from light. Do not store above 25°C.
Any reconstituted product remaining 28 days after preparation should be discarded.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Reviews
There are no reviews yet.